Clinical Trial Update: A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke [Phase 2]

View source ↗

Summary

Results from a Phase 2b trial of dalfampridine extended-release 10 mg in subjects with chronic deficits after ischemic stroke were posted. The study assessed sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Ampyra (4-aminopyridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Ischemic Stroke | Phase 2 | Status: COMPLETED | Results posted: 2014-03-10